Literature DB >> 11593591

Clinical hereditary characteristics in nasopharyngeal carcinoma through Ye-Liang's family cluster.

F Zhang1, J Zhang.   

Abstract

OBJECTIVE: To investigate the incidence of nasopharyngeal carcinoma (NPC) and the clinical characteristics in this family through a long-term follow-up, and to seek the hereditary factor of NPC. This research was also designed to provide some clinical data for etiological study.
METHODS: A genealogical tree of Ye-Liang's family was drawn and reported in 1972 after a complete survey. Further follow-up from that time to 1997 was performed. Human leucocyte antigens (HLA) were investigated, and physical follow-up was done in domestic members of this family. For oversea members of this family, correspondence follow-up was performed.
RESULTS: In the last 25 years, the incidence of malignancies in Ye-Liang's family increased from 10 cases to 18 cases, and incidence of NPC increased from 9 cases to 15 cases. In this family, not only multiple malignancies have been found in the second generation, but also NPC has been found in the third generation. HLA-[A2-B46] haplotype was correlated with occurrence of NPC.
CONCLUSIONS: Dominant racial predilection and family cluster in NPC implied that NPC is a heredity-related cancer which might involve multifactorial disorders in carcinogenesis. Further research on etiology of NPC should be focused on hereditary factor. Detection of inherited factors should be performed for forecast of carcinogenesis and reduction of NPC occurrence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11593591

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  8 in total

1.  Candidate pathways and genes for nasopharyngeal carcinoma based on bioinformatics study.

Authors:  Jinhui Chen; Rui Yang; Wei Zhang; Yongping Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  JNK pathway inhibition enhances chemotherapeutic sensitivity to Adriamycin in nasopharyngeal carcinoma cells.

Authors:  Yong Liu; Jing Feng; Ming Zhao; Jingbo Wu; Juan Fan; Qinglian Wen; Jinhui Xu; Jianwen Zhang; Shaozhi Fu; Biqiong Wang; Yun Lu; Kang Xiong; Li Xiang; Yanling Zhang; Linglin Yang
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

3.  Familial nasopharyngeal carcinomas possess distinguished clinical characteristics in southern China.

Authors:  Su-Mei Cao; Sui-Hong Chen; Chao-Nan Qian; Qing Liu; Yun-Fei Xia
Journal:  Chin J Cancer Res       Date:  2014-10       Impact factor: 5.087

4.  Familial tendency and risk of nasopharyngeal carcinoma in taiwan: effects of covariates on risk.

Authors:  Wan-Lun Hsu; Kelly J Yu; Yin-Chu Chien; Chun-Ju Chiang; Yu-Juen Cheng; Jen-Yang Chen; Mei-Ying Liu; Sheng-Ping Chou; San-Lin You; Mow-Ming Hsu; Pei-Jen Lou; Cheng-Ping Wang; Ji-Hong Hong; Yi-Shing Leu; Ming-Hsui Tsai; Mao-Chang Su; Sen-Tien Tsai; Wen-Yuan Chao; Luo-Ping Ger; Peir-Rong Chen; Czau-Siung Yang; Allan Hildesheim; Scott R Diehl; Chien-Jen Chen
Journal:  Am J Epidemiol       Date:  2010-12-10       Impact factor: 4.897

Review 5.  The prevalence and prevention of nasopharyngeal carcinoma in China.

Authors:  Su-Mei Cao; Malcolm J Simons; Chao-Nan Qian
Journal:  Chin J Cancer       Date:  2011-02

6.  microRNA-29a functions as a tumor suppressor in nasopharyngeal carcinoma 5-8F cells through targeting VEGF.

Authors:  Qingyuan Shi; Jinhua Dai; Lizhen Huang
Journal:  Iran J Basic Med Sci       Date:  2019-05       Impact factor: 2.699

7.  Identification of genes involved in Epstein-Barr virus-associated nasopharyngeal carcinoma.

Authors:  Junguo Wang; Fang Mei; Xia Gao; Shoulin Wang
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

8.  Comparison of whole exome sequencing in circulating tumor cells of primitive and metastatic nasopharyngeal carcinoma.

Authors:  Jinyuan Si; Bo Huang; Guiping Lan; Benjian Zhang; Jiazhang Wei; Zhuoxia Deng; Yiliang Li; Ying Qin; Bing Li; Yan Lu; Yongfeng Si
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.